Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: A comparison with nepicastat

Xenobiotica

Volumn 45, Issue 9, 2015, Pages 828-839

  Loureiro, Ana I ^a   Bonifácio, Maria Joaõ ^a   Fernandes Lopes, Carlos ^a   Pires, Nuno ^a   Igreja, Bruno ^a   Wright, Lyndon C ^a   Soares Da Silva, Patrício ^a,b,c  

^a DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

^b University of Porto   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

Author keywords

Blood brain barrier; dopamine; dopamine b hydroxylase; etamicastat; noradrenaline; P glycoprotein; sympathetic nervous system

Indexed keywords

CATECHOLAMINE; DOPAMINE BETA MONOOXYGENASE; ELACRIDAR; ETAMICASTAT; MULTIDRUG RESISTANCE PROTEIN; NEPICASTAT; ACRIDINE DERIVATIVE; ATENOLOL; BENZOPYRAN DERIVATIVE; IMIDAZOLE DERIVATIVE; PLASMA PROTEIN; PROPRANOLOL; PROTEIN BINDING; TETRAHYDROISOQUINOLINE DERIVATIVE; THIOKETONE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APPARENT PERMEABILITY; AREA UNDER THE CURVE; ARTICLE; CACO 2 CELL LINE; CATECHOLAMINE BRAIN LEVEL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PENETRATION; DRUG PROTEIN BINDING; ELIMINATION RATE CONSTANT; ENZYME INHIBITION; GENE OVEREXPRESSION; IN VITRO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MDCK CELL LINE; MOUSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PLASMA PROTEIN BINDING; PREFRONTAL CORTEX; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUME OF DISTRIBUTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; BRAIN; CELL MEMBRANE PERMEABILITY; CHEMISTRY; COMPARATIVE STUDY; DOG; DRUG EFFECTS; HUMAN; LIVER; METABOLISM; TISSUE DISTRIBUTION; TRANSPORT AT THE CELLULAR LEVEL;

MUS;

ACRIDINES; ANIMALS; ATENOLOL; BENZOPYRANS; BIOLOGICAL TRANSPORT; BLOOD PROTEINS; BRAIN; CACO-2 CELLS; CATECHOLAMINES; CELL MEMBRANE PERMEABILITY; DOGS; DOPAMINE BETA-HYDROXYLASE; HUMANS; IMIDAZOLES; LIVER; MADIN DARBY CANINE KIDNEY CELLS; MALE; MICE; P-GLYCOPROTEIN; PROPRANOLOL; PROTEIN BINDING; TETRAHYDROISOQUINOLINES; THIONES; TISSUE DISTRIBUTION;

EID: 84940021210     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2015.1018985     Document Type: Article

References (41)

1. Almeida L, Nunes T, Costa R, et al. (2013). Etamicastat, a novel dopamine beta-hydroxylase inhibitor: tolerability, pharmacokinetics, and pharmacodynamics in patients with hypertension. Clin Ther 35: 1983-96
2. Beliaev A, Ferreira H, Learmonth DA, Soares-da-Silva P. (2009). Dopamine β-monooxygenase: mechanism, substrates and inhibitors. Curr Enzyme Inhibit 5: 27-43
3. Beliaev A, Learmonth DA, Soares-da-Silva P. (2006). Synthesis and biological evaluation of novel, peripherally selective chromanyl imidazolethione-based inhibitors of dopamine beta-hydroxylase. J Med Chem 49: 1191-7
4. Bihorel S, Camenisch G, Lemaire M, Scherrmann JM. (2007). Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier. J Neurochem 102: 1749-57
5. Braggio S, Montanari D, Rossi T, Ratti E. (2010). Drug efficiency: a new concept to guide lead optimization programs towards the selection of better clinical candidates. Expert Opin Drug Discov 5: 609-18
6. DeQuattro V, Sjoerdsma A. (1968). Catecholamine turnover in normotensive and hypertensive man: effects of antiadrenergic drugs. J Clin Invest 47: 2359-73
7. Eisenhofer G, Kopin IJ, Goldstein DS. (2004). Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev 56: 331-49
8. Esler M, Kaye D. (2000). Sympathetic nervous system activation in essential hypertension, cardiac failure and psychosomatic heart disease. J Cardiovasc Pharmacol 35: S1-7
9. Gomes P, Soares-da-Silva P., (2008). Dopamine. In: Baden M., ed. Cardiovascular hormone systems: from molecular mechanisms to novel therapeutics. Weinheim: Wiley-VCH, 251-93
10. Grassi G. (2010). Sympathetic neural activity in hypertension and related diseases. Am J Hypertens 23: 1052-60
11. Grassi G, Bolla G, Quarti-Trevano F, et al. (2008). Sympathetic activation in congestive heart failure: reproducibility of neuroadrenergic markers. Eur J Heart Fail 10: 1186-91
12. Grassi G, Seravalle G, Quarti-Trevano F. (2010). The neuroadrenergic hypothesis' in hypertension: current evidence. Exp Physiol 95: 581-6
13. Hegde SS, Friday KF. (1998). Dopamine-beta-hydroxylase inhibition: a novel sympatho-modulatory approach for the treatment of congestive heart failure. Curr Pharm Des 4: 469-79
14. Hubensack M, Muller C, Hocherl P, et al. (2008). Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice. J Cancer Res Clin Oncol 134: 597-607
15. Igreja B, Pires NM, Bonifacio MJ, et al. (2015). Blood pressure-decreasing effect of etamicastat alone and in combination with antihypertensive drugs in the spontaneously hypertensive rat. Hypertens Res 38: 30-8
16. Igreja B, Pires NM, Wright L, Soares-da-Silva P. (2008). Effect of combined administration of BIA 5-453 and captopril on blood pressure and heart rate. Hypertension 52: E62. (abstract)
17. Igreja B, Pires NM, Wright LC, Soares-da-Silva P. (2011). Antihypertensive effects of a selective peripheral dopamine beta-hydroxylase inhibitor alone or in combination with other antihypertensive drugs. Hypertension 58: E161-2
18. Ishii Y, Fujii Y, Mimura C, Umezawa H. (1975). Pharmacological action of FD-008, a new dopamine beta-hydroxylase inhibitor. I. Effects on blood pressure in rats and dogs. Arzneimittelforschung 25: 55-9
19. Jose PA, Eisner GM, Felder RA. (2002). Role of dopamine receptors in the kidney in the regulation of blood pressure. Curr Opin Nephrol Hypertens 11: 87-92
20. Jose PA, Soares-da-Silva P, Eisner GM, Felder RA. (2010). Dopamine and G protein-coupled receptor kinase 4 in the kidney: role in blood pressure regulation. Biochim Biophys Acta 1802: 1259-67
21. Kalvass JC, Maurer TS. (2002). Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos 23: 327-38
22. Kamiie J, Ohtsuki S, Iwase R, et al. (2008). Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. Pharm Res 25: 1469-83
23. Kruse LI, Kaiser C, DeWolf WE Jr, et al. (1986). Substituted 1-benzylimidazole-2-thiols as potent and orally active inhibitors of dopamine beta-hydroxylase. J Med Chem 29: 887-9
24. Kruse LI, Kaiser C, DeWolf WE Jr, et al. (1987). Multisubstrate inhibitors of dopamine beta-hydroxylase. 2. Structure-activity relationships at the phenethylamine binding site. J Med Chem 30: 486-94
25. Lee CS, Tkacs NC. (2008). Current concepts of neurohormonal activation in heart failure: mediators and mechanisms. AACN Adv Crit Care 19: 364-85
26. Loureiro AI, Joao Bonifacio M, Fernandes-Lopes C, et al. (2014). Etamicastat, a new dopamine-β-hydroxylase inhibitor, pharmacodynamics and metabolism in rat. Eur J Pharmacol 740: 285-94
27. Malpas SC. (2010). Sympathetic nervous system overactivity and its role in the development of cardiovascular disease. Physiol Rev 90: 513-57
28. Mancia G, Grassi G, Giannattasio C, Seravalle G. (1999). Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 34: 724-8
29. Montesinos RN, Moulari B, Gromand J, et al. (2014). Coadministration of P-glycoprotein modulators on loperamide pharmacokinetics and brain distribution. Drug Metab Dispos 42: 700-6
30. Ohlstein EH, Kruse LI, Ezekiel M, et al. (1987). Cardiovascular effects of a new potent dopamine beta-hydroxylase inhibitor in spontaneously hypertensive rats. J Pharmacol Exp Ther 241: 554-9
31. Pacifici GM, Viani A. (1992). Methods of determining plasma and tissue binding of drugs. Pharmacokinetic consequences. Clin Pharmacokinet 23: 449-68
32. Parati G, Esler M. (2012). The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J 33: 1058-66
33. Pfeffer MA, Stevenson LW. (1996). Beta-adrenergic blockers and survival in heart failure. N Engl J Med 334: 1396-7
34. Polli JW, Wring SA, Humphreys JE, et al. (2001). Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299: 620-8
35. Rege BD, Yu LX, Hussain AS, Polli JE. (2001). Effect of common excipients on Caco-2 transport of low-permeability drugs. J Pharm Sci 90: 1776-86
36. Sane R, Agarwal S, Elmquist WF. (2012). Brain distribution and bioavailability of elacridar after different routes of administration in the mouse. Drug Metab Dispos 40: 1612-19
37. Schwab D, Fischer H, Tabatabaei A, et al. (2003). Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem 46: 1716-25
38. Soares-da-Silva P. (1986). Evidence for a non-precursor dopamine pool in noradrenergic neurones of the dog mesenteric artery. Naunyn Schmiedebergs Arch Pharmacol 333: 219-23
39. Soares-da-Silva P. (1987). A comparison between the pattern of dopamine and noradrenaline release from sympathetic neurones of the dog mesenteric artery. Br J Pharmacol 90: 91-8
40. Stanley WC, Li B, Bonhaus DW, et al. (1997). Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-beta-hydroxylase. Br J Pharmacol 121: 1803-9
41. Umeyama Y, Fujioka Y, Okuda T. (2014). Clarification of P-glycoprotein inhibition-related drug-drug interaction risks based on a literature search of the clinical information. Xenobiotica 44: 1135-44